CLINICAL TRIALS PROFILE FOR METHYLIN ER
✉ Email this page to a colleague
All Clinical Trials for METHYLIN ER
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00754208 ↗ | Long Acting Stimulant Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Young Children | Completed | University of Nebraska | Phase 4 | 2008-10-01 | This is a pilot study evaluating the effectiveness, safety, and tolerability of Ritalin LA in treating Attention Deficit Hyperactivity Disorder (ADHD) in 4 and 5 year old children. Virtually no data has been published on the use of long-acting stimulant preparations in very young children despite early symptomatic development in a significant portion of young children with ADHD. This would be one of the first studies looking at a long-acting preparation of a stimulant medication in the treatment of ADHD in very young children. Hypotheses 1. Ritalin LA is effective for the treatment of ADHD in 4 and 5 year old children. 2. Ritalin LA is reasonably well-tolerated in the treatment of ADHD in 4 and 5 year old children. |
| NCT01164956 ↗ | Methylphenidate for Cancer-Related Fatigue | Terminated | Boston Children's Hospital | Phase 1 | 2011-07-01 | The overall aim of this pilot study is to conduct a combined N-of-1 trial (N-1-T) of MPH (methylphenidate) for amelioration of fatigue in children with cancer, and to evaluate the N-1-T design both for individual clinical decision making and for clinical trials in symptom management in pediatric oncology patients. Because no one knows which of the study options are best, participants will receive liquid MPH on some days and a placebo on other days. We will compare how the participant feels on MPH days with how they feel on placebo days to determine whether MPH makes a difference. |
| NCT01164956 ↗ | Methylphenidate for Cancer-Related Fatigue | Terminated | Boston Children’s Hospital | Phase 1 | 2011-07-01 | The overall aim of this pilot study is to conduct a combined N-of-1 trial (N-1-T) of MPH (methylphenidate) for amelioration of fatigue in children with cancer, and to evaluate the N-1-T design both for individual clinical decision making and for clinical trials in symptom management in pediatric oncology patients. Because no one knows which of the study options are best, participants will receive liquid MPH on some days and a placebo on other days. We will compare how the participant feels on MPH days with how they feel on placebo days to determine whether MPH makes a difference. |
| NCT01164956 ↗ | Methylphenidate for Cancer-Related Fatigue | Terminated | Dana-Farber Cancer Institute | Phase 1 | 2011-07-01 | The overall aim of this pilot study is to conduct a combined N-of-1 trial (N-1-T) of MPH (methylphenidate) for amelioration of fatigue in children with cancer, and to evaluate the N-1-T design both for individual clinical decision making and for clinical trials in symptom management in pediatric oncology patients. Because no one knows which of the study options are best, participants will receive liquid MPH on some days and a placebo on other days. We will compare how the participant feels on MPH days with how they feel on placebo days to determine whether MPH makes a difference. |
| NCT02327195 ↗ | General Anesthesia Emergence Induced by Methylphenidate | Completed | Nicoleta Stoicea | Phase 1 | 2014-05-01 | The purpose of this study is to assess whether methylphenidate affects time of emergence from isoflurane general anesthesia. Time to emergence was defined as the time from termination of isoflurane to extubation. After stopping isoflurane infusion, when the patient breaths spontaneously with adequate tidal volume and respiratory rates, the trachea will be extubated and the time will be recorded. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for METHYLIN ER
Condition Name
Clinical Trial Locations for METHYLIN ER
Trials by Country
Clinical Trial Progress for METHYLIN ER
Clinical Trial Phase
Clinical Trial Sponsors for METHYLIN ER
Sponsor Name
